Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
复制标题
DOI：
10.1016/s0021-9150(97)00119-6
复制
发表时间：
1997-08-01
期刊：
影响因子：
5.3
通讯作者：
Black, DM
中科院分区：
文献类型：
--
作者：
Alaupovic, P;Heinonen, T;Black, DM
阿托伐他汀（立普妥）对富含胆固醇和富含甘油三酯的脂蛋白的影响在这项多中心试验中进行了评价。6周基线期后，47例胆固醇和甘油三酯水平升高的患者接受阿托伐他汀10 mg每日一次（QD）治疗，最初12周（第1阶段）增加至20 mg QD，随后12周（第2阶段）。在10和20 mg剂量下，与治疗前水平相比，阿托伐他汀治疗导致低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、极低密度脂蛋白胆固醇（VLDL-C）、载脂蛋白（ape）B、LDL中的apoB显著降低（LDL-apo B），VLDL中的apo B（VLDL-载脂蛋白B）：脂蛋白（Lp）B：脂蛋白B-复合物（LpB（c））、甘油三酯（TG）、低密度脂蛋白甘油三酯（LDL-TG）、极低密度脂蛋白甘油三酯（VLDL-TG），高密度脂蛋白甘油三酯（HDL-TG）和载脂蛋白C-III。阿托伐他汀10和20 mg QD也导致高密度脂蛋白胆固醇（HDL-C）、载脂蛋白AI和LpAII：B：C：D：E显著升高。由于其使富含胆固醇和富含磷脂的颗粒正常化的独特能力，阿托伐他汀是用于广泛患者（包括患有不同程度的高胆固醇血症和高磷脂血症的患者）的单药治疗的有希望的候选药物。(C)1997 Elsevier Science爱尔兰有限公司
The effects of atorvastatin (lipitor) on cholesterol-rich and triglyceride-rich lipoproteins were evaluated in this multicenter trial. Following a 6-week baseline period, 47 patients with elevated cholesterol and triglyceride levels were treated with atorvastatin IO mg once daily (QD) for the initial 12 weeks (Period 1) increasing to 20 mg QD for the following 12 weeks (Period 2). At both the 10 and 20 mg doses, atorvastatin treatment resulted in significant reductions compared to pretreatment levels in low-density lipoprotein cholesterol (LDL-C), total cholesterol(TC), very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein (ape) B, apoB in LDL (LDL-apo B), apo B in VLDL (VLDL-apo B): lipoprotein (Lp)B: lipoprotein B-complex (LpB(c)), triglycerides (TG), low-density lipoprotein triglycerides (LDL-TG), very low-density lipoprotein triglyceride (VLDL-TG), high-density lipoprotein triglycerides (HDL-TG), and apo C-III. Atorvastatin 10 and 20 mg QD also resulted in significant increases in high-density lipoprotein cholesterol (HDL-C), apo AI, and LpAII:B:C:D:E. Due to its unique ability to normalize both cholesterol-rich and triglyceride-rich particles, atorvastatin is a promising candidate for monotherapy in a broad range of patients including those with varying degrees of hypercholesterolemia and hypertriglyceridemia. (C) 1997 Elsevier Science Ireland Ltd.